On the stock market since 2017, it operates in the world of health and science. It has 209 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Sales run at $33.8M a year. A small number, but proof the product has real buyers.
There is $399.8M in the vault; even if every debt were paid off, $277.1M would remain.
A loss of $138.5M against $33.8M in annual sales.
The stock trades 29% above the average analyst price target.
On our five-subject report card, VRNA sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: VRNA is a high-risk stock — not yet profitable, and its future rides on its product catching on.